(2R,3S)-EHNA hydrochloride : A hydrochloride salt obtained by reaction of (2R,3S)-EHNA with one equivalent of hydrochloric acid. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11957547 |
| CHEMBL ID | 1257094 |
| CHEBI ID | 64139 |
| Synonym |
|---|
| EU-0100504 |
| smr000326891 |
| MLS000860033 |
| erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride |
| nsc-263164 |
| NCGC00093903-01 |
| erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride |
| erythro-9-(2-hydroxy-3-nonyl) adenine hcl(2r,3s)-3-(6-amino-9h-purin-9-yl)nonan-2-ol hydrochloride |
| erythro-9-(2-hydroxy-3-nonyl) adenine hcl(2r,3s)-3-(6-amino-9h-purin-9-yl)nonan-2-ol hydrochlorideerythro |
| ehna hydrochloride |
| E-114 , |
| CHEMBL1257094 |
| chebi:64139 , |
| (2r,3s)-3-(adenin-9-yl)-2-nonanol hydrochloride |
| (2r,3s)-ehna.hcl |
| (2r,3s)-3-(6-amino-9h-purin-9-yl)nonan-2-ol hydrochloride |
| (2r,3s)-ehna hydrochloride |
| (2r,3s)-9-(2-hydroxy-3-nonyl)adenine hydrochloride |
| (r,s)-6-amino-beta-hexyl-alpha-methyl-9h-purine-9-ethanol hydrochloride |
| LP00504 |
| CCG-208066 |
| tox21_500504 |
| NCGC00261189-01 |
| AKOS024456497 |
| DTXSID9040473 |
| 9h-purine-9-ethanol, 6-amino-beta-hexyl-alpha-methyl-, monohydrochloride, (r*,s*)- |
| unii-d94v1gc7i3 |
| 9h-purine-9-ethanol, 6-amino-beta-hexyl-alpha-methyl-, hydrochloride (1:1), (alphar,betas)-rel- |
| 9h-purine-9-ethanol, 6-amino-.beta.-hexyl-.alpha.-methyl-, monohydrochloride, (r*,s*)- |
| erythro-9-(2-hydroxy-3-nonyl)adenine monohydrochloride |
| erythro-9-(2-hydroxy-3-nonyl)adenine monohydrochloride, (+/-)- |
| 9h-purine-9-ethanol, 6-amino-.beta.-hexyl-.alpha.-methyl-, hydrochloride (1:1), (.alpha.r,.beta.s)-rel- |
| D94V1GC7I3 , |
| 59262-87-2 |
| 9-(2-hydroxy-3-nonyl)adenine hydrochloride, erythro- |
| erythro-9-(2-hydroxy-3-nonyl)adenine,hc l potent inhibitor of a |
| ehnahydrochloride |
| 9h-purine-9-ethanol, 6-amino-.beta.-hexyl-.alpha.-methyl-, hydrochloride (1:1), (.alpha.r,.beta.s)- |
| 9h-purine-9-ethanol, 6-amino-.beta.-hexyl-.alpha.-methyl-, monohydrochloride, (r-(r*,s*))- |
| (2r,3s)-3-(6-aminopurin-9-yl)nonan-2-ol;hydrochloride |
| (-)-erythro-9-(2-hydroxy-3-nonyl)adenine monohydrochloride |
| unii-ugq2atp3nk |
| UGQ2ATP3NK , |
| erythro-9-(2-hydroxy-3-nonyl)adenine monohydrochloride, (-)- |
| 9h-purine-9-ethanol, 6-amino-beta-hexyl-alpha-methyl-, monohydrochloride, (r-(r*,s*))- |
| 9h-purine-9-ethanol, 6-amino-beta-hexyl-alpha-methyl-, hydrochloride (1:1), (alphar,betas)- |
| Role | Description |
|---|---|
| EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a phosphoric diester hydrolase (EC 3.1.4.*). |
| EC 3.5.4.4 (adenosine deaminase) inhibitor | An EC 3.5.4.* (non-peptide cyclic amidine C-N hydrolase) inhibitor that interferes with the action of adenosine deaminase (EC 3.5.4.4). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| hydrochloride | A salt formally resulting from the reaction of hydrochloric acid with an organic base. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| endonuclease IV | Escherichia coli | Potency | 7.9433 | 0.7079 | 12.4324 | 31.6228 | AID1708 |
| TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 9.0444 | 0.0015 | 30.6073 | 15,848.9004 | AID1224821; AID1224823 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.5406 | 17.6392 | 96.1227 | AID2364; AID2528 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 29.0929 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| snurportin-1 | Homo sapiens (human) | Potency | 29.0929 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 29.0929 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| geminin | Homo sapiens (human) | Potency | 9.5512 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 28.1838 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 3.5481 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 (µMol) | 0.8000 | 0.0000 | 1.7767 | 9.2000 | AID1872557 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1872557 | Inhibition of human PDE2A | 2022 | European journal of medicinal chemistry, Mar-15, Volume: 232 | Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.59) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||